drugset / Trial / NCT00088595

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

NCT00088595

Phase 2 Completed 45 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study evaluating SOM230 in patients with metastatic carcinoid tumors

Timeline

Start
2004-01
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pasireotide Other / unclassified Subcutaneous

Indications